মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the esti

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - mupirocin calcium, quantity: 21.5 mg/g (equivalent: mupirocin, qty 20 mg/g) - ointment - excipient ingredients: white soft paraffin; bis-diglyceryl polyacyladipate-2 - medsurge mupirocin nasal ointment is indicated for the elimination of nasal carriage of staphylococci, including methicillin resistant staphylococcus aureus (mrsa).

মাল্টা - ইংরেজি - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mupirocin - ointment - mupirocin 20 mg - antibiotics and chemotherapeutics for dermatological use

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - mupirocin calcium (unii: rg38i2p540) (mupirocin - unii:d0gx863oa5) - mupirocin 2 g in 100 g - mupirocin cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin cream [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. the estimated background risk in the u.s. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. data animal data: developmental toxicity studies have been performed with mupirocin administered subcutaneously to rats and rabbits at doses up to 160 mg per kg per day during organogenesis. this dose is 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area. maternal toxicity was observed (body weight loss/decreased body weight gain and reduced feeding) in both species with no evidence of developmental toxicity in rats. in rabbits, excessive maternal toxicity at the high dose precluded the evaluation of fetal outcomes. there was no developmental toxicity in rabbits at 40 mg per kg per day, 11 times the human topical dose based on calculations of dose divided by the entire body surface area. mupirocin administered subcutaneously to rats in a pre- and postnatal development study (dosed during late gestation through lactation) was associated with reduced offspring viability in the early postnatal period at a dose of 106.7 mg per kg, in the presence of injection site irritation and/or subcutaneous hemorrhaging. this dose is 14 times the human topical dose based on calculations of dose divided by the entire body surface area. the no-observed adverse effect level in this study was 44.2 mg per kg per day, which is 6 times the human topical dose. risk summary it is not known whether mupirocin is present in human milk, has effects on the breastfed child, or has effects on milk production. however, breastfeeding is not expected to result in exposure of the child to the drug due to the minimal systemic absorption of mupirocin in humans following topical administration of mupirocin cream [see clinical pharmacology (12.3)] . the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for mupirocin cream and any potential adverse effects on the breastfed child from mupirocin cream or from the underlying maternal condition. clinical considerations to minimize oral exposure of the drug to children, a breast and/or nipple being treated with mupirocin cream should be thoroughly washed prior to breastfeeding. the safety and effectiveness of mupirocin cream have been established in the age-groups of 3 months to 16 years. use of mupirocin cream in these age-groups is supported by evidence from adequate and well-controlled trials of mupirocin cream in adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults [see clinical studies (14)] . in 2 adequate and well-controlled trials, 30 subjects older than 65 years were treated with mupirocin cream. no overall difference in the efficacy or safety of mupirocin cream was observed in this patient population when compared with that observed in younger patients.

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - mupirocin - cutaneous ointment - 20mg/1gram

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - mupirocin - cutaneous ointment - 20mg/1gram

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

bryant ranch prepack - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin ointment usp, 2% is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment usp, 2%. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the estimated background risk in the u.s. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. data animal data: developmental toxicity studies have been performed with mupirocin administered subcutaneously to rats and rabbits at doses up to 160 mg per kg per day during organogenesis. this dose is 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area. maternal toxicity was observed (body weight loss/decreased body weight gain and reduced feeding) in both species with no evidence of developmental toxicity in rats. in rabbits, excessive maternal toxicity at the high dose precluded the evaluation of fetal outcomes. there was no developmental toxicity in rabbits at 40 mg per kg per day, 11 times the human topical dose based on calculations of dose divided by the entire body surface area. mupirocin administered subcutaneously to rats in a pre- and postnatal development study (dosed during late gestation through lactation) was associated with reduced offspring viability in the early postnatal period at a dose of 106.7 mg per kg, in the presence of injection site irritation and/or subcutaneous hemorrhaging. this dose is 14 times the human topical dose based on calculations of dose divided by the entire body surface area. the no-observed adverse effect level in this study was 44.2 mg per kg per day, which is 6 times the human topical dose. risk summary it is not known whether mupirocin is present in human milk, has effects on the breastfed child, or has effects on milk production. however, breastfeeding is not expected to result in exposure of the child to the drug due to the minimal systemic absorption of mupirocin in humans following topical administration of mupirocin ointment [see clinical pharmacology (12.3) ]. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for mupirocin ointment and any potential adverse effects on the breastfed child from mupirocin ointment or from the underlying maternal condition. clinical considerations to minimize oral exposure of the drug to children, a breast and/or nipple being treated with mupirocin ointment usp, 2% should be thoroughly washed prior to breastfeeding. the safety and effectiveness of mupirocin ointment have been established in the age range of 2 months to 16 years. use of mupirocin ointment in these age-groups is supported by evidence from adequate and well-controlled trials of mupirocin ointment in impetigo in pediatric subjects studied as a part of the pivotal clinical trials [see clinical studies (14) ].

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

central texas community health centers - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology ( 12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the est

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

unit dose services - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology ( 12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the est

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

unit dose services - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3) ]. no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the esti